Flat pharmacovigilance fee a possibility in EU: a radical change from original proposals
This article was originally published in SRA
Executive Summary
Drug companies in the EU could be looking at paying the European Medicines Agency a flat fee – presumably annually – to cover the agency’s responsibilities under the new EU pharmacovigilance legislation.